These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 28408124)
41. Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission. Mohamed NV; Herrou T; Plouffe V; Piperno N; Leclerc N Eur J Neurosci; 2013 Jun; 37(12):1939-48. PubMed ID: 23773063 [TBL] [Abstract][Full Text] [Related]
42. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. Ploia C; Antoniou X; Sclip A; Grande V; Cardinetti D; Colombo A; Canu N; Benussi L; Ghidoni R; Forloni G; Borsello T J Alzheimers Dis; 2011; 26(2):315-29. PubMed ID: 21628793 [TBL] [Abstract][Full Text] [Related]
43. ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease. Shinohara M; Hirokawa J; Shimodaira A; Tashiro Y; Suzuki K; Gheni G; Fukumori A; Matsubara T; Morishima M; Saito Y; Murayama S; Sato N J Neuropathol Exp Neurol; 2021 Aug; 80(7):652-662. PubMed ID: 34283221 [TBL] [Abstract][Full Text] [Related]
44. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Götz J; Chen F; van Dorpe J; Nitsch RM Science; 2001 Aug; 293(5534):1491-5. PubMed ID: 11520988 [TBL] [Abstract][Full Text] [Related]
45. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Brion JP; Tremp G; Octave JN Am J Pathol; 1999 Jan; 154(1):255-70. PubMed ID: 9916940 [TBL] [Abstract][Full Text] [Related]
46. Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary Tangles and Results in Cognitive Impairment During Normal Aging. Means JC; Gerdes BC; Kaja S; Sumien N; Payne AJ; Stark DA; Borden PK; Price JL; Koulen P Neurochem Res; 2016 Sep; 41(9):2278-88. PubMed ID: 27220334 [TBL] [Abstract][Full Text] [Related]
47. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration. Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215 [TBL] [Abstract][Full Text] [Related]
48. Cholesterol and tau protein--findings in Alzheimer's and Niemann Pick C's disease. Ohm TG; Treiber-Held S; Distl R; Glöckner F; Schönheit B; Tamanai M; Meske V Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S120-6. PubMed ID: 14574625 [TBL] [Abstract][Full Text] [Related]
49. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590 [TBL] [Abstract][Full Text] [Related]
51. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Luo W; Liu W; Hu X; Hanna M; Caravaca A; Paul SM Sci Rep; 2015 Jun; 5():11161. PubMed ID: 26057852 [TBL] [Abstract][Full Text] [Related]
52. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation. Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881 [TBL] [Abstract][Full Text] [Related]
53. A tau-related protein of 130 kDa is present in Alzheimer brain. Gache Y; Guilleminot J; Ricolfi F; Theiss G; Nunez J J Neurochem; 1992 Jun; 58(6):2005-10. PubMed ID: 1374115 [TBL] [Abstract][Full Text] [Related]
54. Tau-66: evidence for a novel tau conformation in Alzheimer's disease. Ghoshal N; García-Sierra F; Fu Y; Beckett LA; Mufson EJ; Kuret J; Berry RW; Binder LI J Neurochem; 2001 Jun; 77(5):1372-85. PubMed ID: 11389188 [TBL] [Abstract][Full Text] [Related]
55. Quantitative propagation of assembled human Tau from Alzheimer's disease brain in microfluidic neuronal cultures. Katsikoudi A; Ficulle E; Cavallini A; Sharman G; Guyot A; Zagnoni M; Eastwood BJ; Hutton M; Bose S J Biol Chem; 2020 Sep; 295(37):13079-13093. PubMed ID: 32699110 [TBL] [Abstract][Full Text] [Related]
56. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. Congdon EE; Chukwu JE; Shamir DB; Deng J; Ujla D; Sait HBR; Neubert TA; Kong XP; Sigurdsson EM EBioMedicine; 2019 Apr; 42():157-173. PubMed ID: 30910484 [TBL] [Abstract][Full Text] [Related]
57. Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. Brown MR; Bondada V; Keller JN; Thorpe J; Geddes JW J Alzheimers Dis; 2005 Feb; 7(1):15-24. PubMed ID: 15750211 [TBL] [Abstract][Full Text] [Related]